• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Bifunctional drug could treat tumors resistant to current mTOR inhibitors [PreClinical]

byCorinne FoleyandJessica Lau
July 2, 2016
in Chronic Disease, Oncology, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. The first known bifunctional inhibitor for the mechanistic target of rapamycin (mTOR) protein was developed to overcome current known mechanisms of tumor resistance to mTOR inhibitors.

2. Treatment with the novel compound prevented tumor growth in mouse models of drug-resistant tumors.

Evidence Rating Level: 2 (Good)

Study Rundown: mTOR is a protein commonly affected in a variety of cancers, making it a prime target for therapeutics. mTOR inhibitors have been developed and show great efficacy; however, mutations in the protein have rendered some patients unresponsive to these treatments. Specifically, mutations in the kinase domain and FKBP12-rapamycin-binding domain (FRB domain) of mTOR have contributed to the resistance of current mTOR inhibitors. As a result, this study developed the first bivalent inhibitor for a protein kinase that binds to both of these domains.

Three potential drugs were developed that were able to simultaneously bind to both domains. Experiments in drug-sensitive cell lines showed that the compounds inhibited mTOR phosphorylation activity in a dose-dependent manner. The most efficacious drug, RapaLink-1, was then tested in cell cultures and mouse models to determine its effect on cancer cells with drug-resistant mTOR. In vitro, RapaLink-1 inhibited mTOR at low doses compared to rapamycin and a recently developed inhibitor, MLN0128. In mice with xenografts of cancer cells containing the common mutations that confer mTOR inhibitor resistance, only RapaLink-1 consistently limited tumor growth over the course of 60 days.

Further studies will need to be performed to determine the toxicity and potential systemic effects of this drug. However, this study shows the potential of a treatment for patients who are resistant to current mTOR inhibitors. These experiments are also the first to demonstrate the successful production of a pharmaceutically efficacious bivalent protein kinase inhibitor.

RELATED REPORTS

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

Medical cannabis provides little improvement to sleep in chronic pain patients

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

Click to read the study in Nature

Relevant Reading: A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

In-Depth [animal study]: First, researchers analyzed the crystal structure of rapamycin binding to the FRB and kinase domains of mTOR, the main structural regions containing mutations that lead to mTOR inhibitor resistance. In order to overcome the reduced drug binding conferred by the mutations, bivalent inhibitors were designed using the modeling program Molecular Operating Environment. Three potential drugs were designed, RapaLink-1, -2, and -3, each containing varying lengths of linkers between the two functional parts of the drug.

Each drug was initially tested on drug-sensitive MCF-7 cells, a human breast cancer cell line, to determine its effect on mTOR signaling. Western blotting demonstrated successful inhibition of phosphorylation of mTOR complexes 1 and 2. RapaLink-3, however, was found to have a decreased potency, a characteristic expected due to the shorter linker of the drug.

RapaLink-1 was further tested to assess its efficacy against drug-resistant cancer cells. Cells expressing mutant resistant versions of mTOR were used in culture or xenografted into mice. The efficacy of RapaLink-1 was compared to rapamycin and a recently developed mTOR inhibitor, MLN0128. In vitro, RapaLink-1 was more efficacious at inhibiting mTOR signaling. In vivo, RapaLink-1 was more efficacious at limiting tumor growth over the course of 60 days.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Two vaccines protect against Zika virus infection in mice [PreClinical]

Next Post

Brain injection of peptide could induce sustained diabetes remission [PreClinical]

RelatedReports

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
StudyGraphics

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

May 27, 2022
Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

Medical cannabis provides little improvement to sleep in chronic pain patients

May 27, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

May 26, 2022
#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
StudyGraphics

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

May 26, 2022
Next Post
Intrapartum serum prolactin may predict risk of postpartum diabetes

Brain injection of peptide could induce sustained diabetes remission [PreClinical]

Food environment associated with gestational diabetes

Early intensive therapy may improve long-term cardiovascular outcomes in type 1 diabetes

Fruit consumption among US youth differs by age, race

Marketing vegetables associated with increased uptake in schoolchildren

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.